STA
LCTX icon

Summit Trail Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Summit Trail Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$14.8K – 638
2024
Q1 		$14.8K Buy
+10,000
New +$11.3K ﹤0.01% 610

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Summit Trail Advisors's LCTX Position: Q2 2024 in Review

Summit Trail Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q2 2024, closing a stake of 10,000 shares — an estimated $14.8K sold.

Summit Trail Advisors first reported a position in LCTX in Q1 2024 and held it in 1 quarter. The position peaked at $14.8K in Q1 2024. 113 funds tracked by Wall St. Rank hold LCTX as of Q2 2024.

  • Summit Trail Advisors reported no remaining Lineage Cell Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Summit Trail Advisors sold 10,000 Lineage Cell Therapeutics shares in Q2 2024, an estimated $14.8K.
  • Summit Trail Advisors first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 1 quarter.
  • Summit Trail Advisors's Lineage Cell Therapeutics position peaked at $14.8K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2024.

Based on Summit Trail Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.